Perazine

Summary

Perazine (CHEMBL1697766) is a phase-3 clinical-stage small-molecule phenothiazine antipsychotic drug (ATC N05AB10); indicated across 5 conditions including psychotic disorder and anxiety.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: N05AB10
• Indications: 5 conditions
• Clinical trials: 2
• Chemistry: 339.5 Da · C20H25N3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1697766
Name	Perazine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	4744
ChEBI	CHEBI:59118
ATC	N05AB10
Molecular formula	C20H25N3S
Molecular weight	339.5
InChIKey	WEYVCQFUGFRXOM-UHFFFAOYSA-N

SMILES: CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=CC=CC=C42

IUPAC name: 10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine

ChEBI definition: A phenothiazine derivative in which 10H-phenothiazinecarries a 3-(4-methylpiperazin-1-yl)propyl substituent at the N-10 position.

Pharmacological roles (ChEBI): phenothiazine antipsychotic drug, dopaminergic antagonist.

Also known as: Perazine, SID29215456, SID144206523, PERAZINE, US9504692, 3946

Patent coverage: 862 distinct patent families (2,664 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,630 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Lysine-specific histone demethylase 1A.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KDM1A	6.04	IC50	909	nM	CHEMBL_ACT_25063938

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	3	MONDO:0005485	EFO:0005407
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02307396	PHASE4	COMPLETED	Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).